Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ketorolac + fluorometholone
- Development stage
- Phase 4
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
This is a combination of two separate ophthalmic medications: ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), and fluorometholone, a corticosteroid. These medications are not typically formulated together as a single product but have been studied comparatively for treating ocular inflammation after cataract surgery and for seasonal allergic conjunctivitis. Ketorolac works by blocking prostaglandin biosynthesis, while fluorometholone is a glucocorticoid that provides anti-inflammatory effects.
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on ketorolac + fluorometholone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ketorolac + fluorometholone.